account_id none on file
legal_name AN2 Therapeutics, Inc.
ticker ANTX
cik 1880438
domain an2therapeutics.com
linkedin_company_url https://www.linkedin.com/company/an2-therapeutics-inc/
entry_point_account_id none on file
name AN2 Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 4 executives 4 family 0
why_nownone on file
callsnone on file
filings
Government cost efficiency initiative under a 2025 Executive Order, the Company was notified that the NIAID will not exercise certain remaining options under the contract, resulting in a total $ 9.0 million reduction to the $ 18.3 million contract, for a total cumulative contract funding of up to $ 9.3 million.
filing / Aug 11, 2026 / receipt
Failure to generate sufficient cash flows from operations, raise additional capital, and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its intended business objectives.
filing / Aug 11, 2026 / receipt
Government cost efficiency initiative under a 2025 Executive Order, the Company was notified that the NIAID will not exercise certain remaining options under the contract, resulting in a total $ 9.0 million reduction to the $ 18.3 million contract, for a total cumulative contract funding of up to $ 9.3 million.
filing / May 11, 2026 / receipt
Failure to generate sufficient cash flows from operations, raise additional capital, and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its intended business objectives.
filing / May 11, 2026 / receipt
executives
| Joshua Eizen | Chief Legal Officer | - | receipt |
| Legal Counsel | Chief Legal Officer | - | receipt |
| Lucy Day | Principal Accounting Officer | - | receipt |
| Sarah Williams | VP, Controller & Principal Accounting Officer | receipt |
familynone on file
upcoming
| 2026-11-11 | earnings call | scheduled | ir |
changes
| 2026-01-29 | Vice President, appointed | sec_8k |
| 2024-11-05 | Chief Legal Officer, appointed | sec_8k |
| 2024-11-05 | Chief Legal Officer, appointed | sec_8k |
| 2023-09-08 | Principal Accounting Officer, appointed | sec_8k |
mcp_package_hint
slug an2-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$